LabLogic Systems has launched Version 6 of its Debra LIMS for drug metabolism studies, the first new version to be introduced for 15 years
LabLogic Systems has released the version 4.1 of its Laura software for radiochromatography, adding Windows 7 support and powerful new 2D and 3D display options
LabLogic Systems has released Debra 5.7.7, its LIMS platform for ADME studies. The latest release provides greater flexibility in reporting data and additional features
LabLogic Systems has introduced Release 4.0.5 of its Laura radiochromatography software, which features more than 150 improvements and innovations developed over the past 12 months
Laura 4, the chromatography data collection and analysis system from LabLogic Systems, now includes a facility for e-signatures. The company is also providing more licensing options for evaluation copies.
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
